Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,658

Document Document Title
WO/2015/109666A1
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...  
WO/2015/109935A1
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...  
WO/2015/106678A1
Uses of progesterone in the preparation of drugs for treatment or prevention of altitude sickness caused by hypobaric hypoxia. The progesterone has preventive and treatment effects on acute high altitude disease or high altitude cerebral...  
WO/2015/096725A1
Provided are a linear lipopeptide with an end group having a lipophilic structure, a preparation method for the lipopeptide, and a use thereof in preparing an anti-radiation injury medicament. The lipopeptide is one lipophilic structural...  
WO/2015/095553A1
The present disclosure relates to a dialysis apparatus comprising a membrane having at least one protein from the lipocalin family bound thereon. The disclosure further relates to methods of removing non-polar, hydrophobic and/or protein...  
WO/2015/092763A1
The present invention in one aspect relates to a nutritional composition for the prevention and/or treatment of COPD and symptoms related to it, comprising N- acetylcysteine and/or a physiologically acceptable salt thereof in association...  
WO/2015/088233A1
Disclosed are an antioxidative peptide having a sequence of any one of SEQ ID NOs: 1 to 340, a peptide which is a fragment of sequences of SEQ ID NOs: 1 to 340, or a peptide having at least 80% sequence identity with the peptide sequence...  
WO/2015/083554A1
The problem addressed by the present invention is to provide a 4G-α-glucosylrutin crystal, a 4G-α-glucosylrutin crystal-containing powder, an application of same as a drug starting material, and applications as a cosmetic product start...  
WO/2015/074115A1
The invention described in this specification relates to the prevention and treatment of alkaloid-induced toxicosis in pasture grazing animals.  
WO/2015/076667A1
The present invention relates to a composition for managing menopause in a human or animal body, characterized in that said composition comprises a germinated brown rice derived compound.  
WO/2015/076294A1
[Problem] To suppress the onset of adverse effects of drugs that cause gastric ulcers as an adverse effect. [Solution] The onset of gastric ulcers induced by a drug is suppressed by incorporating, into a pharmaceutical composition contai...  
WO/2015/070280A1
The present invention relates to a method of treating or preventing DNA damage in a cell or cellular senescence of a cell or induction of the senescence associated secretory phenotype (SASP) in a cell, or for treating or preventing the e...  
WO/2015/069974A1
Capsules containing nutritional supplement formulations are disclosed which include a lipophilic MDG carrier oil comprising a mixture of monoglycerides and diglycerides, but with no more than 10% triglycerides. One or more lipophilic nut...  
WO/2015/065937A1
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the ...  
WO/2015/064764A1
Provided is an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound having pharmacological action. The present invention relates to an aryloyl(oxy or amino)pentafluorosulfanylbenzene compound represented by general formula (A-I), a p...  
WO/2015/066190A1
The present invention is directed to methods for the treatment or prevention of oxidative stress in a cell, e.g., photoreceptor cell, and methods for the treatment and prevention of disorders associated therewith by the administration of...  
WO/2015/058034A1
The present invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering...  
WO/2015/057726A1
A composition comprising an effective amount of a combination of mitochondrial nutrients sufficient to affect mitochondrial function. A method of affecting an aging process in a subject comprising administering to a subject an effective ...  
WO/2015/053336A1
Provided are: an anti-fatigue composition resulting from the combined use of (1) histidine and (2) vitamin B6 and/or carnosine; and a food or the like containing (1) histidine and (2) vitamin B6 and/or carnosine in the form of being pack...  
WO/2015/044180A1
The invention concerns a substance for reducing tissue calcification and tissue fibrosation, delaying the onset of age-related diseases of a living being, and associated methods.  
WO/2015/047647A1
Ionic liquid compositions derived from imidazolium based ionic liquids that have been thermally treated or thermally and oxidatively treated are disclosed. These compositions can be utilized as the medium for oxidation of alkylaromatic c...  
WO/2015/042821A1
Disclosed are a compound for activating AMPK, which is an adenine and/or a pharmaceutically acceptable salt, and disclosed is a use of the compound for preventing or treating physiological conditions or diseases in mammals which can be a...  
WO/2015/046365A1
 The purpose of the present invention is to provide an emulsifiable formulation of a liposoluble substance that improves the emulsifiability of the liposoluble substance. The water dispersibility of a liposoluble carotenoid can be impr...  
WO/2015/028850A1
Provided are cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infe...  
WO/2015/027565A1
An L-carnitine micro-capsule powder and preparation method thereof, the L-carnitine micro-capsule powder comprising: L-carnitine, maltodextrin, arabic gum, gelatin, and sodium ascorbate; the preparation method comprises the following ste...  
WO/2015/030106A1
The present invention relates to compounds represented by general formula (I) (where Z, R, Ra, R', * and n are each as defined in the description) or salts thereof.  
WO/2015/028027A1
The present disclosure concerns monoclonal antibodies directed to the pro-domain of ADAM 12 and their use in the treatment of cancer.  
WO/2015/028286A1
A polymer of formula (I) where X1 and X2 respectively represent the alpha and omega end groups of the polymer; R1 represents a hydrogen atom or a straight or branched chain alkyl group; R2 represents a straight or branched chain alkyl gr...  
WO/2015/025528A1
The present invention addresses the problem of providing a novel free radical scavenger which can solve problems occurring in existing free radical production inhibitors/scavengers, such as the induction of inflammation. Specifically, th...  
WO/2015/024100A1
A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent i...  
WO/2015/020138A1
 The purpose of the present invention is to provide a means for promoting the in vivo absorption of hydroxytyrosol or a derivative thereof, prolonging the in vivo residence time, and sustaining the effect. As a result of in-depth studi...  
WO/2015/015989A1
The purpose of the present invention is to provide an agent for alleviating side effects in cancer chemotherapy, said agent being capable of alleviating various side effects in cancer chemotherapy and thus increasing the treatment comple...  
WO/2015/014209A1
Provided in the present invention is a method for detoxification in healthy human beings and lung disease patients using pyruvate pharmaceutical compositions. Toxins accumulated in mammalian cells because of smoking and air pollution can...  
WO/2015/010498A1
A natural herb composition for rapidly cleaning body metabolic toxins is prepared by using the following raw materials in part by mass, the raw materials comprise a mangosteen extract, an aloe extract, and a hot-water extract of a mixtur...  
WO/2015/008317A1
The present invention addresses the problem of providing a hydrogen sulfide production-inducing agent that has a higher efficiency and a lower toxicity than L-cysteine. The present invention is characterized in that, by administering D-c...  
WO/2015/005060A1
Provided is a method for producing an ellagic acid composition which has excellent solubility in water. A method for producing an ellagic acid composition, which comprises: a step wherein a heat treatment starting material is prepared by...  
WO/2015/002061A1
Provided is a medicinal active ingredient which is useful for treating or preventing inflammatory diseases, diseases caused by lipid oxidation, retinochoroidal disorders, etc. The present invention is a phenylimidazole derivative represe...  
WO/2014/205551A1
A method of treating sepsis comprises administering an agent that inhibits the activity of an miRNA that is upregulated in sepsis.  
WO/2014/197250A1
An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed i...  
WO/2014/195416A1
The invention relates to a chelate resulting from the complexing of a trans-di-N-picolinate tetraazacycloalkane ligand with a metal cation, said ligand corresponding to formula (A) wherein n is equal to 0 or to 1, R is H or a C1-C18 alky...  
WO/2014/194809A1
Provided in the present invention are new compounds having the triple activities of thrombolysis, antithrombotic and radical scavenging as represented by general formula (I), wherein T is a connecting arm having at least two groups for c...  
WO/2014/188046A1
The invention relates to neuroprotective, antioxidant steroidal nitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer and Parkinson disease and am...  
WO/2014/187291A1
The present invention discloses a mercaptonicotinic acid compound and preparation method and use thereof; the structural formula of the compound is as shown in Formula I. Experimentation demonstrates that the mercaptonicotinic acid compo...  
WO/2014/183555A1
The present invention relates to a cycloalkyl acid derivative, a preparation method thereof, and a pharmaceutical application thereof, and in particular, the present invention relates to a cycloalkyl acid derivative represented by genera...  
WO/2014/180238A1
The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof...  
WO/2014/180248A1
The present invention relates to an oral pharmaceutical composition for increasing hypoxia tolerance, characterized in that the pharmaceutical composition comprises active ingredient L-carnitine or derivative thereof or pharmaceutically ...  
WO/2014/180239A1
The present invention provides a pharmaceutical composition used for treating severe altitude sickness, characterized by a composition consisting of trimetazidine or pharmaceutically acceptable salt thereof and L-carnitine or derivative ...  
WO/2014/180240A1
The present invention discloses a slow-release agent for increasing hypoxia tolerance; the slow-release agent is a composition formed by combining trimetazidine or pharmaceutically acceptable salt thereof and L-carnitine or derivative th...  
WO/2014/175180A1
A quercetin glycoside and a fructooligosaccharide in a ratio (by weight) of 1 to at least 0.1 are incorporated to produce a quercetin glycoside-containing oral composition and to mitigate the bitterness of the quercetin glycoside contain...  
WO/2014/173174A1
The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presenc...  

Matches 1 - 50 out of 9,658